Insilico Medicine has launched Longevity Vaccines, a research initiative applying generative artificial intelligence (AI) and programmable RNA medicine to develop single-administration, self-limiting in vivo cell therapies designed to clear the earliest cellular drivers of age-related disease, the company announced September 15, 2026.¹ The initiative will first target rejuvenation of the aging immune system by clearing senescent lymphocytes and expands Insilico's aging-oriented discovery strategy from small molecules into RNA-encoded, in vivo cell engineering.
Key facts
- Program: Longevity Vaccines (Insilico Medicine)
- Platform: cmRNA in targeted lipid nanoparticles
- Mechanism: Arms patient's own T cells to clear senescent, fibrotic, autoreactive cells
- Initial indication: Immune system rejuvenation (senescent lymphocyte clearance)
- Additional indications under evaluation: Metabolic dysfunction, membranous nephropathy
- Prior validation: Rentosertib (ISM001-055), AI-designed TNIK inhibitor, now in phase 3 for IPF
- Pipeline productivity: 9 development candidates nominated in first 8 months of 2026
- Key partners: Lilly, Servier, Takeda, SK Biopharmaceuticals, others
- Regulatory status: Early-stage research initiative; no clinical timeline disclosed
"We built Insilico to treat aging and disease together, and to prove that AI can design medicines that deliver real patient impact," said Alex Zhavoronkov, PhD, founder and co-CEO of Insilico Medicine, in a company press release.¹ "Longevity Vaccines initiative extends that same rigor to preventive medicine—delivering programmable, single-dose therapies that clear the root-cause cells of age-related disease, starting with the immune system itself."
How does the Longevity Vaccines platform work?
The initiative uses a single, programmable delivery modality, which is a short-lived genetic instruction encoded in circular messenger RNA (cmRNA) and packaged within a targeted lipid nanoparticle (LNP). Once delivered, it arms a patient's own T cells to recognize and remove specific target cell populations, including senescent cells that secrete pro-inflammatory proteins, activated fibroblasts that drive fibrosis, and autoreactive lymphocytes that erode self-tolerance.¹
Circular mRNA is designed to resist degradation to support durable yet self-limiting expression, while the targeted LNP is intended to ensure selective delivery, according to the company. Rather than treating downstream pathology, Longevity Vaccines are designed to eliminate these initiating cell populations within a preventive window and on a transient basis.¹
What evidence supports this cell-clearing approach?
This approach builds on a growing body of peer-reviewed research showing that engineered T cells can clear senescent and other pathogenic cell populations and deliver durable functional benefits from a single therapeutic course.¹ In one such study, senolytic chimeric antigen receptor T cells targeting a senescence-associated cell-surface protein improved exercise capacity and metabolic function in aged mice, with a single low-dose administration sufficient to achieve long-term therapeutic and preventive effects.²
What is Insilico's track record with AI-designed therapeutics?
The initiative builds on Insilico's experience with rentosertib (ISM001-055), a first-in-class traf2- and NCK-interacting protein kinase (TNIK) inhibitor whose target was nominated by AI and whose molecule was fully AI-designed, advancing from target identification to preclinical candidate in 18 months.¹ In a phase 2a trial, patients receiving the highest dose of rentosertib showed a mean forced vital capacity increase of 98.4 mL, compared with a mean decline of 20.3 mL in the placebo group.³ The drug has since advanced to phase 3 development for idiopathic pulmonary fibrosis.³ Based on this experience, Insilico has established a dual-purpose strategy of discovering therapeutics that address both specific clinical indications and fundamental biological aging processes.¹
What other indications and business milestones did Insilico report?
Beyond immune rejuvenation, Insilico is evaluating additional indications sharing defined initiating cell populations reachable by the same chassis, including metabolic dysfunction and membranous nephropathy.¹ The company reported total revenue of approximately $106 million in the first half of 2026, a 287% year-over-year increase, and its first profitable half-year since listing, with an adjusted net profit exceeding $51 million, driven by collaborations with partners including Eli Lilly and Company, Servier, and Takeda.¹ Insilico also nominated 9 development candidates within the first 8 months of 2026 has launched benchmarks and foundation models intended to accelerate longevity drug discovery.¹
What are the limitations?
Longevity Vaccines is an early-stage research initiative, and the company has not disclosed preclinical efficacy or safety data specific to this program. The peer-reviewed research it builds on involves different constructs and animal models rather than the company's own candidate. No clinical trial timeline for Longevity Vaccines has been announced.
References
- Insilico Medicine. Insilico launches AI-driven Longevity Vaccines research for aging-related diseases and human longevity. Press release. Published September 15, 2026. Accessed September 15, 2026. https://insilico.com/news/lgv150926en-ai-driven-longevity-vaccines
- Amor C, Fernández-Maestre I, Chowdhury S, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat Aging. 2024;4(3):336-349. doi:10.1038/s43587-023-00560-5
- Xu Z, Ren F, Wang P, et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nat Med. 2025;31(8):2602-2610. doi:10.1038/s41591-025-03743-2
